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Abstract
Background: The global spread and increasing incidence of carbapenem-resistant Enterobacteriaceae have resulted
in treatment and public health concerns. Here, we present an investigation of the molecular mechanisms and
clonality of carbapenem-non-susceptible Escherichia coli (CnSEC) based on a nationwide survey in Taiwan.
Methods: We collected 32 and 43 carbapenem-non-susceptible E. coli isolates in 2010 and 2012, respectively. The
genes encoding cabapenemases and plasmidic AmpC-type and extended-spectrum β-lactamases (EBSLs) were
analyzed by polymerase chain reaction (PCR). The major porin channels OmpF and OmpC were evaluated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Molecular typing was performed with pulsed-field gel
electrophoresis (PFGE) and multi-locus sequence typing (MLST).
Results: The resistance rates of CnSEC isolates to cefazolin, cefotaxime, cefoxitin, ceftazidime, and ertapenem were all
100%, and most (94.7%) isolates were CMY producers. The main mechanism of CnSEC in Taiwan is via plasmidic AmpC
β-lactamase CMY-2 and DHA-1 in combination with the loss of OmpC/F. In 2010, one isolate was confirmed to
harbor blaIMP-8; a KPC-2 producer and an NDM-1 producer were detected in 2012. No isolate had VIM- or
OXA-carbapenemases. ST131 was the predominant ST type (33.3%). PFGE revealed no large cluster in CnSEC isolates
in Taiwan.
Conclusions: The co-existence of plasmidic AmpC β-lactamase and outer membrane protein loss is the main
mechanism for CnSEC in Taiwan. The emergence of KPC-2 and NDM-1 in 2012 and the predominance of
ST131 warrant close monitoring and infection control.
Background
Escherichia coli is an important member of Enterobacte-
riaceae that is evolving drug resistance mechanisms.
Extended-spectrum β-lactamases (ESBLs) conferring re-
sistance to extended-spectrum cephalosporins lead to
treatment failure by penicillins and cephalosporins and
are prevalent in E. coli isolates from hospital patients,
community members, farm animals, and food. Carbapenems
are powerful antibiotics that are not inactivated by ESBLs
and AmpC β-lactamases and therefore are regarded as the
last line of treatment for infections by ESBL producers. Car-
bapenem resistance in Enterobacteriaceae, particularly Kleb-
siella pneumoniae, has recently been reported worldwide,
whereas carbapenem-resistant E. coli is relatively rare [1].
Nonetheless, carbapenem resistance in E. coli should be
closely monitored because of its potential to spread in both
hospital and community settings [2].
The mechanisms of carbapenem resistance in Entero-
bacteriaceae are the presence of either carbapenemase
or a combination of β-lactamases and porin loss [3-7].
There are three types of carbapenemases that hydrolyze
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carbapenems, including class A (penicillinases), class B
(metallo-β-lactamases), and class D (oxacillinase). Al-
though IMP- and VIM-MBLs have typically been the
most common types of MBLs found in Enterobacteriaceae
[8], KPC (class A) enzymes are now the most predominant
carbapenemases worldwide [9]. Carbapenemase-harboring
E. coli is relatively less reported, though the first report of
KPC-2 in E. coli was in 2006 [10]. This could be because
carbapenem resistance does not occur naturally in E. coli
[11], and it has been reported that plasmid transfer be-
tween K. pneumoniae and E. coli does not readily
occur [12].
With regard to ESBL-producing E. coli, pandemic
E. coli MLST type ST131 with CTX-M β-lactamase is
spreading [13]; thus, whether the spread of carbapenem
resistance in E. coli is related to certain clones warrants in-
vestigation. Accordingly, we initiated a nationwide surveil-
lance program in 2010 and 2012 to investigate the
molecular epidemiology of imipenem- or meropenem-
non-susceptible E. coli in Taiwan.
Methods
Bacterial strains and susceptibility testing
Participating hospitals in the national survey identified
imipenem- or meropenem-non-susceptible E. coli and sent
all these isolates to a reference laboratory in National Health
Research Institutes, Taiwan. A total of 32 imipenem- or
meropenem-non-susceptible E. coli isolates were consecu-
tively collected from eight hospitals participating in 2010
(five medical centers and three regional hospitals), with 43
collected from 17 hospitals (eight medical centers and nine
regional hospitals) in 2012 [14]. All the isolates were from
individual cases. This study was approved by the institu-
tional review board of Kaohsiung Medical University Hos-
pital (IRB No. KMUH-IRB-2 0130328). The isolates were
obtained as part of routine hospital care procedures, and
written informed consent for participation in the study was
waived. The primary screening for carbapenem resistance
was performed by the individual participating hospitals
using the disc diffusion method. Species identification was
performed by standard biochemical methods: the API sys-
tem or the Vitek2 automated system. Further confirmation
of antimicrobial susceptibility was determined by the broth
micro-dilution method according to the guidelines of the
Clinical and Laboratory Standards Institute (CLSI) [15]. In
early 2012, CLSI revised the ertapenem breakpoints; thus, to
compare the MIC results from different years, we used CLSI
(M100-S22-U, 2011) [14] to interpret the ertapenem suscep-
tibility results. For the susceptibility testing results, only iso-
lates from the eight hospitals that participated in both 2010
and 2012 surveillance projects were analyzed and compared.
The following anti-microbial agents were tested: cefazolin,
cefotaxime, ceftazidime, cefepime, cefoxitin, ertapenem, imi-
penem, meropenem, doripenem, gentamicin, amikacin,
ciprofloxacin, trimethoprim-sulfamethoxazole, colistin,
and tigecycline. Quality control was performed using
E. coli ATCC 35218 and ATCC 25922 reference strains.
Detection of genes encoding carbapenemases, AmpC,
and ESBLs
Carbapenemases (class B families, IMP, VIM, NDM,
GIM, SPM, and SIM; class A families, NMC, IMI, SME,
KPC, and GES; class D, OXA-48), plasmidic AmpC
(CMY, DHA, and ACT) [16], and ESBL genes (CTX-M,
TEM, and SHV) were detected by PCR amplification
[17]. Primers for the class B carbapenemase NDM-1
were newly designed for this study (NDM-1F, TCTCGA
CATGCCGGGTTT; NDM-1R, GAGATTGCCGAGCG
ACTT). The amplicons were sequenced, and the entire
sequence of each gene was compared to the sequences
in the GenBank nucleotide database at http://www.ncbi.
nlm.nih.gov/blast/.
Transfer of blaNDM-1 and plasmid DNA analysis
Plasmid conjugation was performed using E. coli J53 AzR as
the recipient strain. The recipients and blaNDM-1-carrrying
donor samples were separately inoculated into brain-heart
infusion broth and incubated at 37°C for 4 h. The samples
were then mixed at a ratio of 10:1 (Donor:Recipient,
by volume) for overnight incubation at 37°C. A 0.1-ml ali-
quot of the overnight broth mixture was spread onto a
MacConkey agar plate containing sodium azide (100 μg/ml)
and imipenem (1 μg/ml). The plasmids were extracted
from these transconjugants using the standard alkaline lysis
method, and fingerprints of the plasmids were generated
by digestion with HincII or PvuII (New England Biolabs,
Beverly, MA).
Pulsed-field gel electrophoresis (PFGE)
Total DNA was prepared, and PFGE was performed as
described [18]. The restriction enzyme XbaI (New England
Biolabs, Beverly, MA) was used at the temperature
suggested by the manufacturer. The restriction fragments
were separated by PFGE in a 1% agarose gel (Bio-Rad,
Hercules, CA) in 0.5× TBE buffer (45 mM Tris, 45 mM
boric acid, and 1.0 mM EDTA, pH 8.0) for 22 h at
200 V at a temperature of 14°C, with ramp times of 2–40 s
using a CHEF Mapper apparatus (Bio-Rad Laboratories,
Richmond, CA). The Dice coefficient was used to calculate
similarities, and the unweighted pair-group method
with the arithmetic mean method was used for the cluster
analysis with BioNumerics software version 5.10 (Applied
Maths, St-Martens-Latem, Belgium). Similarity PFGE
patterns Hospital ST Cluster.
Isolation and analysis of outer membrane proteins
Bacterial outer membrane proteins (OMPs) were pre-
pared as described [19]. The OMPs were then separated
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by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) through 7.5% polyacrylamide-6 M
urea gels and visualized by Coomassie Blue staining
(Bio-Rad). A reference strain, E. coli ATCC25922, was
included as a control. Figure 1 shows representative
SDS-PAGE results to illustrate the interpretation of
OmpC and OmpF loss.
Multi-locus sequence typing (MLST)
MLST with seven housekeeping genes [20], adk (adenylate
kinase), fumC (fumarate hydratase), gyrB (DNA gyrase), icd
(isocitrate dehydrogenase), mdh (malate dehydrogenase),
purA (adenylosuccinate synthetase), and recA (ATP/GTP
motif), was performed on all isolates according to the proto-
col described on the E. coli MLST website (http://mlst.ucc.
ie/mlst/dbs/Ecoli/documents/primersColi_html). The allele
sequences and sequence types (STs) were verified at the
http://mlst.ucc.ie/mlst/dbs/Ecoli/ website.
Results and discussion
All isolates were resistant to cefazolin, cefotaxime, cef-
tazidime, cefoxitin, and ertapenem. With the exception
of amikacin, the rates of resistance to the other tested
antimicrobial agents increased in 2012. For the eight
hospitals that participated in both the 2010 and 2012
surveillance projects, the resistance rates of imipenem,
meropenem, doripenem, and cefepime increased signifi-
cantly (P < 0.05) (Table 1). Indeed, the resistant rates to
imipenem, meropenem, and doripenem were 56.3%,
31.3%, and 15.6%, respectively, in 2010 and increased to
72.1%, 58.1%, and 51.2%, respectively, in 2012. All iso-
lates were susceptible to tigecycline and colistin in 2010,
whereas the resistant rates to tigecycline and colistin
were 7.0% and 2.3%, respectively, in 2012.
Of the 75 E. coli isolates, five were not typable by
PFGE. No major cluster was found, except for two pul-
sotypes with 4 and 2 isolates each (Figure 2). The PFGE
results suggested that clonal spread was not responsible
for the emergence of carbapenem-resistant E. coli.
Based on MLST, ST131 was found to be the major se-
quence type. Of the 75 E. coli isolates, ST131 was de-
tected in 25 isolates (9 isolates in 2010 and 16 isolates in
2012). Seven isolates were assigned to ST410, and six
isolates were assigned to ST457. ST405 and ST101 were
found in three isolates each. The remaining isolates ex-
hibited diverse ST types. The isolates of MLST type
ST131 showed no significant difference in distribution in
2010 and 2012 and displayed highly diverse PFGE
patterns.
In 2010, all the isolates were negative for KPC-, NDM-,
VIM-, and OXA- carbapenemases, though one isolate was
confirmed to harbor blaIMP-8. In 2012, one KPC-2-
producing isolate and one NDM-1-producing isolate
were detected, whereas no IMP-, VIM-, and OXA-type
carbapenemases were found.
In Asia, KPC-producing Enterobacteriaceae was first
detected in K. pneumoniae in China in 2004 [21] and
was also soon found in Citrobacter freundii, E. coli, and
Serratia marcescens [22,23]. In Taiwan, the first three
KPC-2-positive patients were detected in K. pneumoniae
isolated from patients having been hospitalized in China
[24,25]. Since then, KPC-2-producing K. pneumoniae
has been increasingly reported in Taiwan [26], though
few cases of KPC-positive E. coli have been reported
[27]. In the present report, we identify the first KPC-2-
positive E. coli from Taiwan. This KPC-2-containing
E. coli was obtained from a 78-year-old female who
had not been abroad but was transferred from a re-
gional hospital to a middle Taiwan medical center for
a urinary tract infection. The KPC-2-containing iso-
late also produced TEM-1, CMY-2, and CTX-M-3/
CTX-M-22 β-lactamases and was classified as MLST
sequence type 410 (ST410). To date, KPC-producing
E. coli has only been reported in Israel, the USA, China,
Brazil, France, Greece, and Ireland [10,12,22,28-31], and
two major sequence types containing KPC-carbapenemases
have been reported. ST131 was reported in France [31], the
USA [27], and Ireland [30]; ST410 was reported in Greece
[10] and Israel [1] (ST471 in the Pasteur Institute typing
Figure 1 Outer membrane profile of ATCC control isolates and clinical isolates of E. coli from this study. Lane 1 shows the expression of
OmpC, OmpF, and OmpA in the ATCC25922 control strain. Lane 2 shows OmpF deficiency; Lane 3 shows OmpC deficiency; Lane 4 shows both
OmpF and OmpC deficiency.
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system is the same as ST410 in the UCC typing system).
The possibility that ST131 and ST410 are future epidemic
clones of KPC-2-producing E. coli worldwide is of great
concern.
We also report the first NDM-1-harboring E. coli
isolate in Taiwan. Interestingly, an NDM-1-positive
K. pneumoniae was detected in the same hospital dur-
ing the same period and was included in the study to
compare the two NDM-1-containing plasmids. The
two NDM-1 plasmids from K. pneumoniae and E. coli
were successfully transferred to the recipient isolate E. coli
J53. Additionally, the plasmid digestion profiles of the two
NDM-1 plasmids revealed different patterns (Figure 3), in-
dicating that plasmid spread is less likely. Our E. coli
NDM-1 producer possessed TEM-1 and CMY-2 but did
not encode CTX-M β-lactamases and 16S rRNA methyl-
ase genes, which are commonly found in blaNDM-1-posi-
tive isolates [32]. Thus far, ten sequence types (ST101,
ST405, ST648, ST90, ST410, ST156, ST131, ST167,
ST224, and ST38) of E. coli have been reported to con-
tain NDM-1 [33]. However, the ST type of the NDM-1
clone described herein is ST345, which has not yet
been reported to harbor NDM-1. This finding supports
a conclusion that blaNDM-1 occurs in E. coli belonging
to diverse phylogenetic lineages [34] and also empha-
sizes the need to study the plasmids carrying blaNDM-1
in E. coli.
All 75 isolates carried AmpC β-lactamase CMY and/or
DHA-1; most of the isolates produced CMY-2 (68 isolates,
90.7%), and one CMY-4-carrying isolate was detected in
2012. DHA-1 was detected in six isolates in 2010 and one
isolate in 2012. CTX-M-type ESBLs were detected in 13
isolates (40.6%) in 2010 (ten isolates exhibited CTX-M-14,
and three each exhibited the CTX-M-14/CTX-M-15,
CTX-M-14/CTX-M-55, or CTX-M-27/CTX-M-55 com-
binations), and ten isolates (23.3%) harbored CTX-M
genes in 2012 (three isolates harboring CTX-M-14,
three with CTX-M-79, two with CTX-M-15, and one
each with the CTX-M-14/CTX-M-79, CTX-M-3/CTX-
M-15 combination).
The 75 carbapenem-non-susceptible E. coli isolates
showed the loss of at least one porin, whereas 42 (56%)
isolates had lost both OmpC and OmpF. Sixteen (21.3%)
isolates exhibited OmpF loss, and ten (13.3%) isolates
exhibited OmpC loss.
Our study revealed that the main mechanism of imipe-
nem or meropenem non-susceptibility in Taiwan is AmpC
β-lactamase CMY-2 and DHA-1 in combination with
OmpC/F loss (Table 2). It has been previously verified that
such a combination of mechanisms can contribute to car-
bapenem resistance [6,7]. Most of the isolates were CMY
producers (94.7%), and this most common CMY enzyme
(CMY-2) of carbapenem-non-susceptible E. coli is also
frequently found in cephamycin-resistant E. coli in
community-acquired urinary tract infections in Taiwan [35].
E. coli sequence type ST131 is a pandemic clone asso-
ciated with the CTX-M-15 gene and is resistant to
fluoroquinolones [36]. Clone ST131 potentially harbors
Table 1 Antimicrobial susceptibility testing results for carbapenem-non-susceptible E. coli isolates in 2010 and 2012
Antibiotics ertapenem-non-susceptible E. coli (8 hospitals) and imipenem- or meropenem-non-susceptible E. coli (17 hospitals)
2010 (n = 32) 2012 (n = 43)
MIC range
(μg/ml)
MIC50 (μg/ml) MIC90 (μg/ml) Resistance (%) MIC range (μg/ml) MIC50 (μg/ml) MIC90 (μg/ml) Resistance (%)
Ertapenem 2-≥ 8 ≥8 ≥8 100 1-≥ 8 ≥8 ≥8 100
Imipenem 1-≥ 8 4 ≥8 56.3 1-≥ 8 ≥8 ≥8 72.1
Meropenem 0.12-≥ 8 2 8 31.3 0.5-≥ 8 4 ≥8 58.1
Doripenem 0.12-≥ 4 1 4 15.6 0.5-≥ 4 ≥4 ≥4 51.2
Amikacin ≤4-64 4 32 6.3 ≤4-32 ≤4 16 0
Gentamicin ≤1- ≥ 16 2 ≥16 40.6 ≤1-≥ 16 4 ≥16 45.7
Cefazolin ≥32 ≥32 ≥32 100 ≥32 ≥32 ≥32 100
Cefotaxime 4-≥ 64 ≥64 ≥64 100 32-≥ 64 ≥64 ≥64 100
Cefoxitin ≥32 ≥32 ≥32 100 ≥32 ≥32 ≥32 100
Ceftazidime 16-≥ 32 ≥32 ≥32 100 ≥32 ≥32 ≥32 100
Cefepime 0.25-≥ 32 8 ≥32 18.8 2-≥ 32 16 ≥32 46.5
Ciprofloxacin 0.06-≥ 4 ≥4 ≥4 75.0 ≤0.06-≥ 4 ≥4 ≥4 79.1
Tigecycline ≤0.25-1 ≤0.25 0.5 0 ≤0.25-≥ 4 ≤0.25 0.5 7.0
Colistin ≤0.5-2 1 2 0 ≤0.5-≥ 4 ≤0.5 1 2.3
SXTa 0.06-≥ 16 ≥16 ≥16 62.5 ≤2/38-≥ 4/76 ≥4/76 ≥4/76 76.7
aSXT: Trimethoprim/sulfamethoxazole. Trimethoprim/sulfamethoxazole MICs are presented according to the concentration of trimethoprim in 2010.
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Figure 2 A dendrogram of the pulse-field gel electrophoresis (PFGE) fingerprinting results and the ST types of 70 typable E. coli isolates.
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a variety of β-lactamase genes, most commonly CTX-
M β-lactamases, followed by TEM, SHV, and CMY
β-lactamases [13], and its dissemination has contrib-
uted to the spread of CTX-M-15-producing E. coli
[37]. Of the 75 carbapenem-non-susceptible E. coli iso-
lates, 25 (33.3%) were the ST131 type; of these, 23 iso-
lates displayed a resistant to ciprofloxacin. However,
most of the isolates (18/25, 72%) did not produce
CTX-M-type β-lactamases. Thus, our results showed
that E. coli ST131 is the predominant ST type of carba-
penem non-susceptible E. coli in Taiwan but that it is
not highly associated with CTX-M ESBLs. Our find-
ings are similar to the results of Kim et al. [27] and
support the conclusion that the ability of the ST131
clone to acquire resistance genes under selective pres-
sure could be high.
We found that the low prevalence of CTX-M-type
β-lactamases was most likely linked to the identifica-
tion of a low amikacin resistant rate in this study.
Amikacin resistance mediated by 16S rRNA methyl-
ase (armA and rmtB) in Gram-negative bacteria is an
emerging resistance mechanism [38], and our previ-
ous study found that the 16S rRNA methylase gene
(armA and/or rmtB) and the CTX-M gene were lo-
cated on the same plasmid [39]. The low prevalence
of CTX-M-type β-lactamases and the low amikacin
resistant rate suggested the lack of an endemic plasmid to
transfer both blaCTX-M and 16S rRNA methylase genes for
carbapenem-non-susceptible E. coli.
Conclusions
OmpC and/or OmpF deficiency combined with AmpC
(major CMY-2 and DHA-1) was found to be the
major mechanism for the development of carbapenem
non-susceptibility in Taiwan. The dominant clone of
carbapenem-non-susceptible E. coli in Taiwan is ST131,
Figure 3 HincII- or PvuII-digested plasmid profiles of
transconjugants of NDM-1-carrying K. pneumoniae and E. coli.
Table 2 Outer membrane profiles for carbapenem-non-
susceptible E. coli isolates in 2010 and 2012
β-lactamases Outer membrane profilea
2010 (8 hospitals;
n = 32)
2012 (17 hospitals;
n = 43)
F/C △C △F △C/F F/C △C △F △C/F
Carbapenemase
KPC-2 0 0 0 0 1 0 0 0
NDM-1 0 0 0 0 0 0 1 0
IMP-8 0 0 0 1 0 0 0 0
AmpC only
CMY 1 4 10 12 3 6 5 27
DHA 0 0 1 3 0 0 0 0
ESBL
CTX-M 0 0 0 0 0 0 0 0
SHV 0 0 0 0 0 0 0 0
aMost isolates have multiple β-lactamase genes. The priority for the determination
of β-lactamase in this table is carbapenemases, AmpC enzymes, and then ESBLs.
No duplicate calculation was performed for each isolate.
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which has also been found worldwide, and the high preva-
lence of this ST type illustrates the epidemic potential of
this clone. The introduction of KPC-2 and NDM-1 into
E. coli in Taiwan warrants further monitoring with re-
gard to the epidemiology of carbapenem resistance, the
resistance mechanisms, and the potential epidemic
clones.
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